title: [IL-17 and IL23 expression as a predictor of response to infliximab treatment in Crohn's disease].
abstract: OBJECTIVE
  To evaluate the value of IL-17 and IL23 expression in response prediction of infliximab treatment in Crohn's disease (CD).
  
  
  METHODS
  A total 23 CD patients were enrolled in this study including 19 males and 4 females. Another 17 patients with colonic polyps were recruited as control group. The tissue expression of IL-17 and IL23 positive cells were counted and recorded in 10 random high power fields (HPFs).
  
  
  RESULTS
  Infliximab was effective in sixteen patients (69.6%), while 7 patients (30.4%) did not response. The numbers of IL-17 or IL23 positive cells were much more in responders than those in nonresponders. The median numbers of IL-17 or IL23 positive cells were 26.7 (18.0, 38.6)/HPF in responders, 11.8 (7.0, 14.0)/HPF in nonresponders, 3.0 (2.0, 4.0)/HPF in controls (P = 0.004). The median numbers of IL-23 positive cells were 74.5 (44.8, 128.6)/HPF in responders, 22.4 (19.0, 38.8)/HPF in nonresponders, 3.0 (2.0, 4.0)/HPF in controls (P = 0.018). IL-17 or IL-23 positive mucosal cells were significantly decreased after infliximab treatment.
  
  
  CONCLUSIONS
  High expression of IL-17 and IL-23 in mucosa may predict the response to infliximab in CD patients.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.forename: Jia
authors.initials: J
authors.lastname: Hu
authors.forename: Lang
authors.initials: L
authors.lastname: Suo
authors.forename: Zhen
authors.initials: Z
authors.lastname: Yang
authors.forename: Ting
authors.initials: T
authors.lastname: Xu
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D016022:Case-Control Studies; D003424:Crohn Disease / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D020381:Interleukin-17 / Q000378:metabolism*; D053759:Interleukin-23 / Q000378:metabolism*; D008297:Male
chemical_list: D005765:Gastrointestinal Agents; C508717:IL17A protein, human; D020381:Interleukin-17; D053759:Interleukin-23; D000069285:Infliximab